David Whitcombe has more than 10 years of academic research and 15 years in industrial R&D. David has produced a number of publications and patents including the Scorpions technology that formed the basis of his start-up business DxS Ltd in 2000. He was Head of Technology Development at AstraZeneca Diagnostics for four years leading a team focused on developing new genomic technologies. David successfully developed DxS over 8 years before securing an exit in September 2009 for a total enterprise value in excess of £100M.
